Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.

Q2 Holdings (QTWO)

Consensus Price Target: $89.29 (45.7% implied return)

With a platform powering digital services for approximately 25 million account holders across America, Q2 Holdings (NYSE: QTWO) provides cloud-based digital solutions that help financial institutions, fintechs, and alternative finance companies deliver modern banking experiences to their customers.

Why Does QTWO Worry Us?

1. ARR growth averaged a weak 11.3% over the last year, suggesting that competition is pulling some attention away from its software
2. Estimated sales growth of 10.7% for the next 12 months implies demand will slow from its two-year trend
3. Gross margin of 53.4% is way below its competitors, leaving less money to invest in areas like marketing and R&D

Q2 Holdings’s stock price of $61.26 implies a valuation ratio of 5x forward price-to-sales. Check out our free in-depth research report to learn more about why QTWO doesn’t pass our bar.

Teladoc (TDOC)

Consensus Price Target: $8.93 (63.8% implied return)

Founded to help people in rural areas get online medical consultations, Teladoc Health (NYSE: TDOC) is a telemedicine platform that facilitates remote doctor’s visits.

Why Do We Think Twice About TDOC?

1. Sales trends were unexciting over the last three years as its 2.9% annual growth was below the typical consumer internet company
2. Decision to emphasize platform growth over monetization has contributed to 7.9% annual declines in its average revenue per user
3. Demand will likely fall over the next 12 months as Wall Street expects flat revenue

Teladoc is trading at $5.45 per share, or 4.4x forward EV/EBITDA. Read our free research report to see why you should think twice about including TDOC in your portfolio.

Caleres (CAL)

Consensus Price Target: $17 (39.1% implied return)

The owner of Dr. Scholl's, Caleres (NYSE: CAL) is a footwear company offering a range of styles.

Why Do We Pass on CAL?

1. 3.8% annual revenue growth over the last five years was slower than its consumer discretionary peers
2. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
3. High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens

At $12.22 per share, Caleres trades at 11.2x forward P/E. Dive into our free research report to see why there are better opportunities than CAL.

Stocks We Like More

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.